NOVARTIS logo.jpg
Novartis: solide croissance du chiffre d’affaires et du bénéfice. La forte performance des marques existantes soutient la confiance dans les prévisions de croissance à moyen terme
April 26, 2022 01:00 ET | Novartis Pharma AG
Annonce événementielle selon l’art. 53 RC Chiffre d’affaires du T1 en hausse de +5% (tcc1, +1% USD) et résultat opérationnel core en progression de 9% (tcc, +3% USD) Innovative Medicines (IM):...
NOVARTIS logo.jpg
Novartis receives positive CHMP opinion for Tabrecta® for patients with METex14 advanced non-small cell lung cancer
April 22, 2022 09:27 ET | Novartis Pharma AG
Opinion based on Phase II GEOMETRY mono-1 study showing an overall response rate (ORR) of 51.6% in a cohort evaluating second-line patients only and 44% in all previously-treated patients with...
Sandoz
Sandoz launches generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension, expanding leading ophthalmic portfolio
April 14, 2022 01:15 ET | Novartis Pharma AG
 Brimonidine tartrate/timolol maleate combination eyedrop is used to treat elevated eye pressure in patients with ocular hypertension1 Ocular hypertension affects over 5% of all adults2; the eye does...
NOVARTIS logo.jpg
FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)
April 05, 2022 20:29 ET | Novartis Pharma AG
Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a spectrum of rare conditions and is characterized by...
NOVARTIS logo.jpg
Novartis expands Zolgensma manufacturing capacity with approval of multi-product North Carolina facility
April 05, 2022 01:15 ET | Novartis Pharma AG
Clearance of critical milestone expands capability for production of gene therapies, starting with Zolgensma® Basel, April 5, 2022 – Novartis today announced the U.S. Food and Drug Administration...
NOVARTIS logo.jpg
Novartis gibt neue Organisationsstruktur bekannt für schnelleres Wachstum, eine stärkere Pipeline und höhere Produktivität
April 04, 2022 01:00 ET | Novartis Pharma AG
Ad-hoc-Mitteilung gemäss Art. 53 KRDie neue, vereinfachte Struktur und Organisation werden die Strategie von Novartis als fokussiertes Arzneimittelunternehmen unterstützen und die nächste Phase...
NOVARTIS logo.jpg
Novartis announces new organizational structure to accelerate growth, strengthen pipeline and increase productivity
April 04, 2022 01:00 ET | Novartis Pharma AG
 Ad hoc announcement pursuant to Art. 53 LRNew simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of...
NOVARTIS logo.jpg
Novartis receives positive CHMP opinion for Jakavi® to treat acute and chronic graft-versus-host disease
March 25, 2022 08:09 ET | Novartis Pharma AG
CHMP opinion based on Phase III REACH2 and REACH3 trials that showed Jakavi improved response rates and failure-free survival compared to best available therapy1,2 Graft-versus-host disease (GvHD) is...
NOVARTIS logo.jpg
Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe
March 25, 2022 08:03 ET | Novartis Pharma AG
Positive opinion paves way for third indication in Europe for Kymriah, a potentially definitive single infusion CAR-T cell therapy treatment optionCHMP opinion based on Phase II global ELARA trial...
NOVARTIS logo.jpg
Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer
March 23, 2022 16:19 ET | Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR FDA also approved complementary diagnostic imaging agent, Locametz®, after radiolabeling with gallium-68 for the identification of PSMA-positive...